Ambrose Healthcare Ltd (Ambrose Healthcare), a specialist pharmaceutical company in rare diseases and hospital care, is pleased to announce the broadening of its network of collaborators with the joining of Aparito.
The collaboration enables Ambrose Healthcare and Aparito together to overcome a key challenge of developing and measuring clinical trial endpoints in rare disease studies. Aparito joins Ambrose Healthcare’s network of rare disease collaborators to tackle the many unmet needs of rare disease patients and specialists.
Aparito and Ambrose Healthcare are both part of the Welsh Healthcare ecosystem and based in Wrexham, Wales.
Toby Wilson Waterworth, Chair and Chief Executive of Ambrose Healthcare said: “In rare diseases there are often no precedents or validated endpoints for determining drug effectiveness in clinical trials. This new collaboration builds on Ambrose Healthcare’s network of experts working together to deliver new rare disease treatments.”
Dr Elin Haf Davies, Chief Executive of Aparito said: “Our Atom5™ platform was originally designed for rare disease trials and has been deployed in a wide range of studies to quantify how a patient feels, functions and responds to treatment using digital biomarkers and novel outcome measures as endpoints. We are excited to be working as part of this innovative network for the benefit of rare disease patients.”
About Ambrose Healthcare
Ambrose Healthcare is a specialist pharmaceutical company, developing new treatments for rare diseases, and for patients managed in hospitals and specialist care.
The company has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry and a track record of success.
Ambrose Healthcare is developing a portfolio of commercial and clinical-stage therapeutic assets through acquisition, licensing and collaborations.
About Aparito (www.aparito.com)
Aparito’s mission is to digitise clinical trials and accelerate drug development for patients with life-limiting diseases by supporting patient-centric clinical trials with innovative treatments.
Clinical trials can be conducted within patients’ homes by leveraging our Atom5™ platform incorporating disease-specific smartphone apps, video assessments and wearable technology to deliver digital clinical trials using novel eCOA to generate continuous real-world data.
Aparito’s patient-generated data platform is disease-agnostic and scalable, ready for rapid deployment in global rare disease studies.
Forward looking statements
While Ambrose Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Ambrose Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Ambrose Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.
For more information, please contact:
Adam Michael, Director of Communications
adam.michael@ambrosehc.com +44 7775 881 813